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Objective.Toinvestigatetheindicationandlimitationsofuterinearteryembolization(UAE),weretrospectivelyanalyzedthecaseof
patientswithuterineleiomyomaswhohadundergoneUAE.Methods.Duringthepast7years,25patientswithuterineleiomyomas
had undergone UAE in our hospital. UAE was indicated in patients with menstrual disturbances such as hypermenorrhea or
dysmenorrhea. The outcomes of this procedure for uterine leiomyomas were analyzed. Results. Improvement in the menstrual
symptoms and/or reduction in the leiomyoma size after UAE were observed in 24 patients (96.0%). There was mean 67.9%
reduction in the volume of leiomyomas at six months after UAE (P<0.05). However, the symptoms recurred after UAE in 6
patients (24.0%), with multiple or intramural leiomyomas larger than 7cm, which necessitated additional procedures. Conclusion.
The indications and limitations of the UAE should be considered because of its noneﬀectiveness and/or recurrence in over 20% of
patients with uterine leiomyomas.
1.Introduction
Several nonsurgical techniques are used for the treatment
of patients with uterine leiomyomas, such as the recently
developed magnetic resonance-guided focused ultrasound
therapy. Uterine artery embolization (UAE) is an outpatient
nonsurgical radiologic treatment of uterine leiomyomas. It is
noninvasive and useful for women who refuse hysterectomy,
as well as for those with a high surgical risk, including
morbid obesity [1].
We retrospectively analyzed the cases of 25 patients with
symptomatic uterine leiomyomas who had undergone UAE
to clarify the indications and limitations of the procedure.
2.MaterialsandMethods
Dataof25patientswithuterinemyomaswhohadundergone
UAE between 2003 and 2009 in National Defense Medical
College Hospital (Saitama, Japan) are listed in Table 1.T h e
mean age of the patients was 41.7 years, and the standard
deviation was 3.5 years. UAE was indicated in patients
with menstrual disturbances such as hypermenorrhea or
dysmenorrhea after obtaining their informed consent. UAE
was also performed in 3 patients with severe complications
and a high surgical risk. Their preexisting medical compli-
cations were as follows: diabetes mellitus and renal failure;
chronic kidney disease and peritoneal dialysis; cerebral palsy
and thrombosis. We detected 12 submucosal myomas and
13 intramural leiomyomas. The mean hemoglobin value
before the UAE was 8.5g/dL, and the standard deviation was
3.0g/dL.
The general indications and contraindications for UAE
in patients with uterine leiomyomas in the Department of
Radiology in our hospital are shown in Table 2. The UAE
was performed under local anesthesia as follows: the uterine
artery was catheterized through a right unilateral approach
after puncturing the right femoral artery, which enabled
embolization particles to be injected into a single or both the
left and right uterine arteries. Gelfoam (Pﬁzer Inc., USA)
was used as the embolization particle, and up to one sheet of
that was broken into pieces for the unilateral embolization.
The outcomes including complications of the procedure
for uterine leiomyomas were analyzed. The overall reduction
inthevolumeofleiomyomawasevaluatedatsixmonthsafter2 Obstetrics and Gynecology International
Table 1: Patient characteristics (n = 25).
Age (y) 41.7 ± 3.5
(mean ± standard deviation)
Parity 0.96 ± 1.2
Indication of UAE
Hypermenorrhea/anemia 20
Dysmenorrhea 5
Medical complications 3
DM · renal failure; CKD · PD;
CP · thrombosis
Type of uterine leiomyomas
Submucosal 12
Intramural 13
Size (diameter, cm) 8.4 ± 5.3
Anemia (hemoglobin value, g/dL) 8.5 ± 3.0
UAE: uterine artery embolization; DM: diabetes mellitus; CKD: chronic
kidney disease; PD: peritoneal dialysis; CP: cerebral palsy.
Table 2: General indications and contraindications of uterine
artery embolization in patients with uterine leiomyomas.
Indications
(1) Hypermenorrhea and/or dysmenorrhea
(2) Absence of a malignant tumor in the uterus and lesion in
the adnexa
(3) Absence of a pelvic inﬂammatory disease
(4) No childbearing
Contraindications
(1) No symptoms
(2) Large leiomyoma (more than 10cm in diameter) and/or
multiple leiomyomas
(3) Coexistence of a malignant tumor in the uterus or a lesion
in the adnexa
(4) Active pelvic inﬂammatory disease
(5) Hormone therapy (required for 8–12 weeks after the
therapy)
(6) During pregnancy
(7) Menopause
(8) Hope of childbearing
(9) Allergy to iodine
Department of Radiology, National Defense Medical College Hospital,
Japan.
UAE by MRI or ultrasound. Hemoglobin values were also
measured at two months after the procedure. We used the
Student’s t-test for statistical analysis. A two-tailed P<0.05
was considered statistically signiﬁcant.
3. Results
The clinical outcomes of UAE in patients with uterine
leiomyomas are shown in Table 3. They were followed up
at least for 24 months. Improvement in the menstrual
symptoms and/or reduction in the size of the leiomyoma
were observed in 24 patients (96.0%). At six months after
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Figure 1: Changes in the leiomyoma volume (n = 17) and Hb
values (n = 25) during course of the UAE treatment. UAE: uterine
artery embolization; Hb: hemoglobin; SD: standard deviation.
UAE, there was mean 67.9% reduction in the volume of
leiomyomas in 17 patients, which was signiﬁcant (Figure 1,
P<0.05).In8patients(32.0%),thesubmucosalleiomyomas
were protruding and were thus removed after UAE. The
anemia was signiﬁcantly reduced at two months after UAE
due to a decrease in the excessive uterine bleeding (Figure 1,
P<0.001). However, the symptoms recurred in 6 patients
(24.0%),withmultipleorintramuralleiomyomaslargerthan
7cm.TheUAEwasineﬀectivein1patient(4.0%)withalarge
leiomyoma. These patients required additional procedures
such as repeat embolization (2 patients) and hysterectomy (3
patients).Althoughallthepatientsdevelopedcommoncom-
plications such as abdominal pain, nausea, and fever, they
exhibited immediate recovery without major complications.
A patient revealed elevated liver enzymes and other patient
complained of leg pain and recovered within several months.
No patient went into menopause after UAE.
4. Discussion
UAE involves a short treatment using conscious sedation,
an incision in the groin to access femoral vessels, and an
overnight stay for pain control [2]. Our study showed that
improvement in the menstrual symptoms and/or reduction
in the size of the leiomyoma after the UAE were observed
in most cases. Studies including randomized clinical trials in
Europe document long-term symptom control for 1–5 years
with improvement in bleeding, pain, and bulk symptoms
[3, 4]. In other observational studies, UAE was followed by a
signiﬁcantreductioninuterinevolume(35–60%),adecrease
in excessive uterine bleeding in 90% of the women, a low
rate of subsequent hysterectomy, and a high rate of sustained
symptom control (up to 80%) 5 years after the procedure, as
observed in our study [5].
However, persistent symptoms after UAE occur in
approximately 20% of women who subsequently require
o t h e rp r o c e d u r e ss u c ha sr e p e a te m b o l i z a t i o n ,h y s t e r e c t o m y ,
or myomectomy [1]. In our study, the symptoms recurred
in 24% of the patients who required repeat embolization
and hysterectomy. Solitary leiomyomas measuring moreObstetrics and Gynecology International 3
Table 3: Clinical outcomes of UAE in patients with uterine leiomyomas (n = 25).
Improvement of symptoms and/or reduction in the leiomyoma size 24 (96.0%)
Reduction in the leiomyoma volume at 6 months after UAE (n = 17) 67.9 ± 16.3% (P<0.05)
R e m o v a lo fs u b m u c o s a ll e i o m y o m a 8( 3 2 .0%)
Improvement of anemia
Hemoglobin value at 2 months after UAE (g/dL) 8.5 ± 3.0 →11.5 ± 1.5
(P<0.001)
Prognosis
No eﬀect 1( 4 .0%, a large myoma)
Hysterectomy 3( 1 2 .0%)
Recurrence 6( 2 4 .0%, repeat UAE 2)
Complications
Abdominal pain, nausea, and fever all the patients, short term
Elevated liver enzymes 1
Leg pain 1
Menopause none
Mean ± standard deviation.
than 10cm or multiple ﬁbroids with a uterine volume
consistent with a 20-week or greater gestation are considered
contraindications to UAE, due to its ineﬀectiveness on these
leiomyomas [2]. UAE is particularly useful in women with a
solitary submucosal leiomyoma smaller than 7cm, and not
those with multiple or intramural leiomyomas larger than
7cm, as observed from another report and our results [6].
All the patients in our study developed common compli-
cations such as abdominal pain, nausea, and fever, followed
by immediate recovery without major complications. One
patient revealed elevated liver enzymes and another patient
complained of leg pain temporarily, and no patient went
into menopause after UAE. The ovarian impairment seen
after UAE may be an asset for perimenopausal women
[2]. However, UAE is of particular concern in women who
wish to conceive. The resulting ovarian damage might not
necessarily result in menopause but may impair future
fertility. The safety of pregnancy after UAE remains unclear.
The rate of a miscarriage, preterm delivery, postpartum
hemorrhage, and placental abnormalities in the subsequent
pregnancy after UAE were reported to be higher than that
after a myomectomy [1]. UAE could be considered for
infertile women who do not wish to undergo surgery or who
are at poor surgical risk. They should be informed about the
beneﬁts and risks of the procedure including those of future
fertility [1].
5. Conclusion
UAE is noninvasive and useful in women who refuse hys-
terectomy, as well as for those with a high surgical risk,
including morbid obesity. It is particularly useful in women
with a solitary submucosal leiomyoma smaller than 7cm,
but not in those with multiple or intramural leiomyomas
larger than 7cm. It is necessary to consider the indications
and limitations of UAE and obtain prior informed consent
in patients with uterine leiomyomas, who wish to undergo
conservative managements, because this procedure is not
eﬀective in approximately 20% of these patients who subse-
quently required other procedures such as a hysterectomy.
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